Trials / Unknown
UnknownNCT05682599
Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 in China
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2 in China
Detailed description
A multicentre, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of Azvudine versus placebo in preventing SARS-CoV-2 infection in household contacts with SARS-CoV-2 infection individuals.Approximately 300 adults with household contact exposure to individuals with a confirmed SARS-CoV-2 infection will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azvudine | Azvudine is a novel nucleoside reverse transcriptase inhibitor. |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2023-01-06
- Primary completion
- 2023-04-15
- Completion
- 2023-05-15
- First posted
- 2023-01-12
- Last updated
- 2023-01-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05682599. Inclusion in this directory is not an endorsement.